Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CStone Pharmaceuticals ( (HK:2616) ) has provided an announcement.
CStone Pharmaceuticals reported strong early-stage clinical data for CS2009, its self-developed trispecific antibody targeting PD-1, VEGF, and CTLA-4, in patients with advanced solid tumors. Phase I results from 113 heavily pretreated patients showed a favorable safety profile, with no dose-limiting toxicities, no maximum tolerated dose reached, and a relatively low incidence of severe treatment-related and VEGF-related adverse events.
Efficacy signals were particularly notable in non-small cell lung cancer, where CS2009 monotherapy achieved a 90% overall response rate and 100% disease control rate in first-line patients with high PD-L1 expression, and a 25% response rate in IO-pretreated, later-line cases. The drug also showed promising activity in traditionally hard-to-treat “cold” tumors such as non-clear cell renal cell carcinoma and soft tissue sarcoma, supporting its broad antitumor potential.
On the back of these data, CStone is moving to accelerate CS2009’s development, planning to launch global Phase III multi-regional trials by the end of 2026 in indications including NSCLC, colorectal cancer, and small cell lung cancer. The company expects to present updated Phase I/II results at major oncology conferences, a step that could enhance its competitive standing in immuno-oncology and draw increased interest from global partners and investors.
The most recent analyst rating on (HK:2616) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a China-based biopharmaceutical company focused on the research, development, and commercialization of innovative oncology therapies. The company’s pipeline includes advanced immuno-oncology drugs and targeted therapies aimed at solid tumors, with an increasing emphasis on global multi-regional clinical development.
Average Trading Volume: 10,487,587
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$10.01B
Find detailed analytics on 2616 stock on TipRanks’ Stock Analysis page.